VEGFA and age-related macular degeneration: These are as follows: (1) vitreous VEGF levels were found to be significantly higher in patients with AMD and CNV compared to healthy controls [194], and (2) clinical trials involving the administration of the anti-VEGF agents, including ranibizumab, bevacizumab, aflibercept, and pegaptanib, markedly suppressed neovascularization and vascular permeability in humans and sustained gain of vision in many AMD patients [195].